Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31 Precursor Cell Lymphoblastic Leukemia-Lymphoma 21 Leukemia, Myeloid, Chronic-Phase 17 Leukemia 12 Breast Neoplasms 12 Prostatic Neoplasms 10 Neoplasm Metastasis 8 Recurrence 6 Pancreatic Neoplasms 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Carcinoma, Non-Small-Cell Lung 6 Melanoma 5 Lung Neoplasms 5 Leukemia, Myeloid, Acute 5 Philadelphia Chromosome 4 Multiple Myeloma 4 Lymphoma 4 Burkitt Lymphoma 4 Blast Crisis 4 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Ovarian Neoplasms 3 Glioma 3 Colonic Neoplasms 3 Triple Negative Breast Neoplasms 2 Salivary Gland Neoplasms 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Polycythemia Vera 2 Neuroblastoma 2 Leukemia, Myelomonocytic, Chronic 2

Interventions

relatlimab 2 linrodostat 2 Nivolumab 2 Ipilimumab 2 Vorinostat 1 Trastuzumab 1 IFL protocol 1 Gemcitabine 1 Dasatinib 1 Cetuximab 1 BMS-813160 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Cancer × Dasatinib × Clear all

NCT02750514 2021-03-22

FRACTION-Lung

Bristol-Myers Squibb

Phase 2 Terminated

295 enrolled 21 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡